Respiratory virus testing and clinical outcomes among children hospitalized with pneumonia
Monday, April 25, 2022
8:00 AM – 8:15 AM US MT
Location: Convention Center: 603
CE: Enduring CME: 0.25
Publication Number: 3130.1
Daniel Shapiro, Boston Children's Hospital, Boston, MA, United States; Matthew Hall, Children's Hospital Association, Lenexa, Kansas, KS, United States; Susan Lipsett, Harvard Medical School, Boston, MA, United States; Adam Hersh, University of Utah School of Medicine, Salt Lake City, UT, United States; Lilliam Ambroggio, Children's Hospital Colorado, Aurora, CO, United States; Samir S. Shah, Journal of Hospital Medicine, Cincinnati, OH, United States; Thomas V. Brogan, University of Washington School of Medicine, Seattle, WA, United States; Jeffrey Gerber, children's hospital of philadelphia, Philadelphia, PA, United States; Carlos Grijalva, Vanderbilt University Medical Center, Nashville, TN, United States; Anne J. Blaschke, University of Utah School of Medicine, Salt Lake City, UT, United States; Jonathan Cogen, Seattle Children's, Seattle, WA, United States; Mark I. Neuman, Boston Children's Hospital, Boston, MA, United States
Presenting Author(s)
Daniel Shapiro, MD
Clinical Fellow Boston Children's Hospital Boston, Massachusetts, United States
Participants should be aware of the following financial/non-financial relationships:
Daniel Shapiro, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Matt Hall, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Susan Lipsett, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Adam Hersh, MD/PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Lilliam Ambroggio, PhD, MPH: ● Pfizer Inc (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator).
Samir S. Shah, MD, MSCE, MHM: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Thomas V. Brogan, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jeffrey S. Gerber, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Carlos Grijalva, MD, MPH: ● AHRQ (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator). ● CDC (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator). ● FDA (Ended In the Past 24 Months) (Products/Services: Research Support including clinical trials & the principal or named investigator). ● Merck (Currently Ongoing) (Products/Services: Consultant). ● NIH (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator). ● Pfizer (Ended In the Past 24 Months) (Products/Services: Consultant). ● Sanofi (Ended In the Past 24 Months) (Products/Services: Consultant). ● Syneos Health (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator).
Anne J. Blaschke, MD, PhD: ● BioFire Diagnostics/Biomerieux (Currently Ongoing) (Products/Services: Advisory Committee, Intellectual Property including patent beneficiary and royalties). ● Merck (Currently Ongoing) (Products/Services: Advisory Committee).
Jonathan Cogen, MD MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mark I. Neuman, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
